. Thus, TGF-␣ is able to promote progression throughout G 1 , but not S phase. Crossbreeding with p53 null mice accelerates tumor development in TGF-␣ transgenic mice dramatically. In tumors developing in these mice, biallelic deletion of Ink4a/Arf or LOH of the Smad4 locus is found suggesting that loci in addition to p53 are involved in antitumor activities. We conclude that these genetic events are critical for pancreatic tumor formation in mice. This model recapitulates pathomorphological features and genetic alterations of the human disease.
Cell cycle progression is regulated by cyclin-dependent kinase (Cdk) complexes. D-type cyclins interact with Cdk4 and Cdk6 to control the progression through G 1 phase (Sherr and Roberts 1999) . Synthesis of D-type cyclins is induced by mitogens, and the continued synthesis throughout G 1 phase depends on persistent growth factor stimulation and/or active Ras. D-type cyclins and the catalytic subunits, Cdk4/6, assemble into active complexes during early G 1 , followed by the activation of cyclin E-Cdk2 complexes during late G 1 phase. Sequentially, Cdk4/6 and Cdk2 complexes collaborate to hyperphosphorylate the retinoblastoma gene product Rb, to initiate an E2F-dependent transcriptional program, and to determine the rate of G 1 to S transition (Johnson et al. 1993) . The entry into the cell cycle is further controlled by the Ink4 protein family that includes p16
Ink4a and the closely related p15 Ink4b , p18
Ink4c
, and p19
Ink4d proteins (Serrano et al. 1993; Guan et al. 1994; Hannon and Beach 1994; Chan et al. 1995) . The four Ink4 proteins exclusively inhibit cyclin D-Cdk4/6 holoenzymes. Furthermore, the Ink4a locus contains an overlapping gene, Arf, encoding p19
Arf (Kamijo et al. 1997) . Arf influences cell survival in the face of aberrant oncogenic signaling mainly as a negative regulator of the p53-destabilizing oncogene Mdm2 (Pomerantz et al. 1998; Weber et al. 1999) .
K-ras mutations are frequently found in human pancreatic cancer (Almoguera et al. 1988) . Oncogenic mutants of Ras remain constitutively in the active, GTPbound form with impaired GTPase activity. Activation of Ras induces DNA synthesis in quiescent fibroblasts. The only phase in which inhibition of Ras affects cell cycle progression is G 1 (Mulcahy et al. 1985) . Once cells have entered S phase, Ras becomes dispensable for cell cycle progression.
In addition to activation of K-Ras, the tumor suppressor loci p53, INK4a, and SMAD4 are frequently inactivated in human pancreatic cancer (Almoguera et al. 1988; Barton et al. 1991; Caldas et al. 1994; Hahn et al. 1996) . Precancerous lesions of pancreatic cancer are not definitively characterized; however, K-ras mutations and allelic inactivation of INK4a have been shown to be present in ductal hyperplasia, indicating the malignant potential of these lesions (Moskaluk et al. 1997) .
Mouse models of exocrine pancreatic tumor development do not reproduce the ductal phenotype of human pancreatic adenocarcinoma but display predominantly acinar characteristics (Quaife et al. 1987) . Transgenic mice overexpressing transforming growth factor (TGF)-␣ under the control of the rat elastase promoter (EL-TGF-␣-hGH) show a transdifferentiation of acinar cells to duct-like cells, which represent premalignant lesions (Sandgren et al. 1990; Wagner et al. 1998 ). Here we show that these mice develop pancreatic cancer similar to the human disease regarding cellular differentiation, growth characteristics, and genetic alterations.
Results

The Ras/Erk1/2 pathway is activated in premalignant lesions in TGF-␣ transgenic mice
To investigate whether Ras is activated in the pancreas of TGF-␣ transgenic mice, we have performed a Ras-affinity precipitation assay, which selectively detects GTP-loaded Ras (Taylor and Shalloway 1996) . Elevated levels of active Ras are detectable shortly after birth and persist throughout adulthood in the pancreas of TGF-␣ transgenic mice as compared with littermate controls (Fig. 1A) . To confirm Ras downstream signaling, immunohistochemical staining for phosphorylated Erk1/2 protein was performed. Figure 1C shows strong staining for phosphorylated Erk1/2 in the pancreas of TGF-␣ transgenic mice as compared with littermate controls (Fig. 1B) . The immunoreactivity for active Erk is evident both in the nucleus and cytoplasm of duct-like cells in tubular complexes (Fig.  1D ). Fibroblasts and acinar cells surrounding the tubular complexes are negative for phosphorylated Erk protein (Fig. 1D ). These data show that the Ras/Erk signaling cascade is activated selectively in tubular complexes that represent the premalignant lesions in TGF-␣ transgenic mice.
Cyclin D1/Cdk4 activity is increased in premalignant lesions in TGF-␣ transgenic mice
Real-time PCR analysis was performed to investigate whether Ras signaling in the pancreas of TGF-␣ transgenic mice leads to up-regulation of cyclin D1. Cyclin D1 mRNA is increased up to 14-fold in the pancreas of mice with developed tubular complexes (180-day-old mice). mRNA levels of cyclins D3 and E remain unchanged ( Fig. 2A) . In mice with developing tubular complexes (28 d), immunohistochemical analysis shows staining for cyclin D1 (Fig. 2B) , Cdk4 (Fig. 2C) , and cyclin E (Fig. 2D ) in a few clusters of acinar cells as well as in the surrounding fibroblasts.
After 180 d, expression of cyclin D and Cdk4 is significantly increased but restricted to cells within tubular complexes, whereas cyclin E is not detectable anymore (Fig. B-J) . To investigate whether this up-regulation of cyclin D1 and Cdk4 results in increased activity of cyclin D1-Cdk4 complexes, immune complex kinase assays were performed. Figure 2K shows strong cyclin D1/Cdk4 activity in the pancreas of TGF-␣ transgenic mice, whereas GST-Rb(769-921) phosphorylation is barely detectable in the pancreas of littermate controls.
TGF-␣ promotes progression throughout G 1 , but not S phase, in premalignant lesions
To detect cell cycle progression, immunofluorescence analysis for PCNA and BrdU labeling were performed. BrdU incorporation is predominantly localized to cells in developing tubular complexes, with labeling indices of 15.5 ±3.4% (Fig. 3A) . At 180 d, fewer cells have incorporated BrdU in tubular structures, with a labeling index of 4.9 ±2.2% (Fig. 3B) . Nontransgenic controls show occasional staining for BrdU in ducts (Fig. 3C ). Although almost all cells within tubular complexes stain positive for cyclin D and Cdk4 (Fig. 2E,F ), only few of these cells display nuclear immunoreactivity for BrdU. Similar results were obtained with PCNA staining (data not shown). Cyclin E is not induced in tubular complexes. (data not shown). These data suggest that TGF-␣ is able to promote progression throughout G 1 , but not S phase, in premalignant lesions.
p53 is induced in tubular complexes and acts as a tumor suppressor in TGF-␣ transgenic mice
Activated Ras in primary cells is able to induce expression of cell cycle inhibitory molecules such as p16 Ink4a , p21
Cip1
, or p53 and p19
Arf . The premalignant lesions in TGF-␣ transgenic mice display increased nuclear immunoreactivity for p53 ( Fig. 3D ) as compared with controls (Fig. 3E) . p21 Cip1 mRNA levels are increased more than eightfold in 180-day-old TGF-␣ transgenic animals compared with littermate controls (Fig. 3F) . In contrast, mRNA levels of p16 Ink4a , p19
Arf , and p27 Kip1 remain unchanged or even slightly decreased throughout adulthood (Fig.  3F ). Western blot analysis confirmed the increase of p21
Cip1 expression and unchanged expression of p27
Kip1 in transgenic mice (data not shown).
To determine the role of p53 in tumor progression, we mated TGF-␣ transgenic mice to p53-deficient mice (Jacks et al. 1994) . TGF-␣ transgenic, p53 +/− and p53 −/− , as well as the crossbred animals were born alive at the expected Mendelian ratio. Up-regulation of p21
Cip1 mRNA is abolished in p53-null mice, although p27
Kip1 mRNA is slightly induced (data not shown). TGF-␣ transgenic mice (31 of 107, 29%) developed malignant pancreatic tumors with a mean tumor-free survival of 410 d. Heterozygous loss of p53 resulted in an increased incidence of pancreatic tumors (66 of 90 animals, 77.3%) and decreased mean tumor-free survival to 220 d in TGF-␣/p53 +/− animals. All 22 TGF-␣/p53 −/− mice developed pancreatic tumors within 120 d after birth (Fig. 3G ). p53 +/− and p53 −/− littermate controls developed mainly mesenchymal tumors with a frequency and latency as described previously ( Fig. 3G ; Jacks et al. 1994) .
Tumor development in TGF-␣/p53 +/− and TGF-␣/ p53 −/− mice precedes tumorigenesis in littermate control p53 +/− and p53 −/− animals. However, necropsy of 3 out of 90 TGF-␣/p53 +/− mice (3.3%) revealed both a large epithelial pancreatic tumor and extrapancreatic sarcoma (data not shown).
Pancreatic carcinomas display a ductal phenotype, grow invasively into the surrounding tissue, and metastasize
Some pancreatic tumors form ductal structures in dense connective tissue (Fig. 4A-C4) ; others show frequent mitotic figures surrounded by sparse fibrosis (Fig.  4D-F) . p53 −/− and p53 +/− littermate controls develop sarcomas and lymphomas ( Fig. 4G-I ; Jacks et al. 1994) . Furthermore, we observed malignant ascites, local invasive growth with duodenal obstruction, and metastasis to the liver and lung in TGF-␣ transgenic mice crossbred to p53-null mice (Fig. 4M-O) . Double staining of serial sections with cytokeratin 8/18 and CD45-LCA indicates epithelial differentiation of the pancreatic tumors (Fig. 4B,E) . Both pancreatic tumors are positive for the ductal marker cytokeratin 19, whereas surrounding fibroblasts express vimentin (Fig. 4C,F) . In contrast, lymphoma from p53-deficient littermate controls express CD45-LCA and vimentin to a lesser degree but do not show any immunoreactivity for cytokeratin 8/18 and 19 (Fig. 4G,I ). In wild-type pancreas, cytokeratin 8/18 is expressed both in acinar and ductal cells, whereas cytokeratin 19 is restricted to ducts (Fig.  4J-L) .
Pancreatic tumors in TGF-␣/p53
+/− mice segregate the wild-type p53 allele and acquire homozygous deletions of the Ink4a/Arf locus Acceleration of tumor formation in TGF-␣/p53 +/− and TGF-␣/p53 −/− transgenic mice identifies the p53 protein as a rate-limiting step during tumorigenesis. To elucidate whether heterozygous p53-null mice lose the inherited wild-type p53 allele during tumorigenesis, we have applied loss of heterozygosity (LOH) analysis to lasercaptured microdissected tumor specimen from F 1 and F 2 Cl57Bl/6-Balb/c hybrid mice informative for polymorphic genetic markers. The residual wild-type p53 allele is segregated in almost all of the tumors arising from TGF-␣/p53 +/− mice (Table 1) . Interestingly, tumors still take more than 45 d to develop in TGF-␣/p53 −/− mice, suggesting that in addition to persistent activation of Ras and inactivation of p53, other genetic events have been acquired during tumorigenesis. To reveal the basis for this delayed onset, LOH analysis was performed with known tumor suppressor loci. Both alleles of the Ink4a/ Arf locus were deleted in 5 out of 15 tumors, and in one case a heterozygous deletion was found, indicating a strong selection pressure for loss of functional p53 and Ink4a/Arf. In addition, we found LOH of the Smad4 locus in four tumors. The well-characterized tumor suppressor locus Rb1 was affected in only two of these tumors (Table 1) .
Discussion
Mice overexpressing TGF-␣ under the control of the elastase promoter develop pancreatic tumors originating from cells within tubular complexes after 1 yr of age (Wagner et al. 1998 ). In the pancreas of these transgenic mice, persistent stimulation of the EGF receptor by TGF-␣ increases GTP loading of Ras and phosphorylation of Erk selectively in tubular structures at 180 d. At 28 d of age these tubular complexes start to develop interspersed between large areas of normal-appearing pancreas. Some cells in these areas seem to be programmed to respond positively to growth activation by Ras signaling and are positive for cyclin D1. At 180 d, numerous tubular complexes form three-dimensional accumulations of ductular structures.
Almost all of these cells show nuclear accumulation of cyclin D1. Neither acinar cells nor fibroblasts are positive for cyclin D1 or Cdk4, suggesting that increased Moreover, no induction of other S-phase proteins such as thymidine kinase 1 or PCNA is detectable, indicating that TGF-␣ is able to promote progression through G 1 but not S phase. These data indicate that early after birth (28 d), cells within developing tubular complexes divide, whereas later, at 180 d, most of these cells become growth-arrested. This conclusion is confirmed by BrdU labeling.
These findings recapitulate previous in vitro data that ras not only is a transforming oncogene but also can exert a negative effect on cell growth. Furthermore, it was observed that these negative effects of Ras could be overcome, in some cases, by simultaneous expression of a cooperating oncogene (Franza et al. 1986 ). Some more recent data provide a possible explanation for these earlier results as it has been shown that introduction of oncogenic Ras into mouse fibroblasts leads to cell cycle arrest, through induction of Cdk inhibitors p16 Ink4a , p21
Cip1
, or p19
Arf and p53 (Macleod et al. 1995; Serrano et al. 1997; Palmero et al. 1998) . In contrast to p16 Ink4a , which is not up-regulated in the pancreas of TGF-␣ transgenic mice, p21
Cip1 is induced up to sevenfold at the mRNA level. Increased expression of p21
Cip1 would provide a logical explanation for the G 1 arrest (Sherr and Roberts 1999) . The molecular basis for the induction of p21
Cip1 is complex. In addition to activation through Raf/MEK/Erk, p21
Cip1 is subject to transcriptional induction by p53 (el Deiry et al. 1993; Macleod et al. 1995) . Nuclear accumulation of p53 is present in cells of tubular complexes, suggesting that p53 represents a candidate for mediating growth arrest in these premaligant lesions. The protein levels of p53 are determined primarily by ubiquitination and subsequent proteolytic degradation. The main ubiquitin ligase for p53 is the oncogene Mdm2. p19
Arf appears to protect p53 from degradation by binding directly to Mdm2 (Pomerantz et al. 1998; Weber et al. 1999 ).
Although it is clear from in vitro studies that overexpression of Ras leads to the induction of p19 Arf , we cannot detect an up-regulation of p19
Arf in the pancreas of TGF-␣ transgenic mice.
Fibroblasts derived from p53 −/− mice were able to overcome the G 1 arrest mediated by Ras and form transformed foci (Serrano et al. 1997) .
In mating experiments we show a dramatically accelerated tumor formation in TGF-␣/p53 −/− mice resulting in pancreatic cancer development before the age of 120 d. TGF-␣ transgenic mice, hemizygous for p53-deficiency, display accelerated disease, and almost 100% of these tumors segregate the wild-type p53 allele. Loss of p53 accelerates tumor formation; however, it takes 45 d to develop cancerous lesions in TGF-␣ transgenic mice null for p53. In the pancreas of these mice, persistent activation of Ras and cyclin D1/Cdk4 is observed shortly after birth. This suggests inactivation of additional genes coding for growth-arrest proteins to be required during tumorigenesis. LOH analysis revealed frequent homozygous losses of the Ink4a/Arf locus in TGF-␣/p53 +/− mice. The deletion also includes Ink4b. The Ink4a/Arf locus encodes the two related putative tumor suppressors p16
Ink4a and p19 Arf (Serrano et al. 1996) . p16 Ink4a represents a potent tumor suppressor in humans and is frequently inactivated in pancreatic neoplasms (Caldas et al. 1994 ). In addition, inherited mutations of exon 1␣ implicate p16
Ink4a in familial tumor susceptibility (Gruis et al. 1995) . However, the final proof of p16
Ink4a as a tumor suppressor in mice awaits the specific inactivation of the p16 Ink4a gene. The loss-of-function approach strongly suggested that p19
Arf is the major tumor suppressor in mice (Serrano et al. 1996; Kamijo et al. 1997) . Deletions of the Ink4a/Arf locus occurred in 6 of 15 tumors in TGF-␣/p53 +/− and TGF-␣/p53 −/− mice. This result was unexpected from previous findings, indicating a mutually exclusive manner of p53 and p19
Arf inactiva- tion in c-myc-induced lymphomagenesis (Eischen et al. 1999) . All tumors retained other polymorphic markers, showing that the effect cannot be simply explained by chromosomal instability. These data therefore indicate that the Ink4a/Arf locus is synergistic to p53 in tumor suppression. Similarly, human pancreatic cancer involves homozygous deletion of the region 9p21-p22, resulting in inactivation of the p14 Arf and p15 INK4b genes (Naumann et al. 1996) . Similar to human pancreatic cancer, LOH of the SMAD4/DPC4 locus occurred with a lower frequency only in our tumor model (Hahn et al. 1996) . Recent data suggest functional inactivation of the TGF-␤-Smad4 pathway in the presence of activated Ras, which might explain a reduced selection pressure for LOH at the Smad4 locus (Kretzschmar et al. 1999) . Furthermore, the Rb1 locus was infrequently affected by LOH. This is consistent with the low number of Rb mutations in human pancreatic cancer.
The tumor spectrum of p53-deficient mice is dominated by lymphomas and sarcomas (Jacks et al. 1994 ). This spectrum shifted to ductal pancreatic cancer in crossbred animals. Only 3 out of 90 mice developed pancreatic tumors and sarcomas. APC-mutated (Min) mice null for p53 develop pancreatic acinar cell adenocarcinomas (Clarke et al. 1995) . Our data complement this observation that p53 is critical in the protection of pancreatic epithelial cells by causing cell cycle arrest.
Carcinogenesis is a multistep process; to reach the malignant phenotype, multiple alterations affecting several levels of growth control are required. Here we report a sequence of genetic events in a murine pancreatic cancer model that recapitulates pathomorphological features and genetic alterations of the human disease.
Materials and methods
Transgenic mice
The EL-TGF-␣-hGH transgenic mice (line #2261-3) and p53-deficient mice have been described (Sandgren et al. 1990; Jacks et al. 1994) . Crossbreeding and inbreeding of congenic C57BL/ 6xEL-TGF-␣-hGH transgenic and Balb/cxp53-deficient mice resulted in F 1 C57BL/6-Balb/c progeny of TGF-␣/p53 +/− and in F 2 progeny of TGF-␣/p53 −/− mice. Mice were sacrificed for analysis at given time points or with obvious signs of wasting disease. The tumor incidence of TGF-␣ (n = 107), TGF-␣/p53 +/− (n = 90), and TGF-␣/p53 −/− (n = 22) transgenic mice was monitored. p53 +/− (n = 64) and p53 −/− (n = 23) littermate controls were followed up to 360 and 180 d, respectively, and evaluated for tumor development. The cumulative tumor incidence in each group was blotted as a function of the age of the animals (Origin 6.0, Northampton, MA). The mean tumor-free survival was calculated from the survival function according to Kaplan and Meier.
Activation assay for Ras, immunocomplex kinase assay, and Western blot
Activation assay for Ras was performed as described recently (Taylor and Shalloway 1996) with a modified, Mg 2+ -containing lysis buffer (MLB: 25 mM HEPES at pH 7.5, 150 mM NaCl, 10 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 1% Nonidet P-40, 0.05 % sodium deoxycholate, 1 mM sodium vanadate, 10 µg/mL aprotinin, 0.5 µmol/mL leupeptin). Cdk4 activity assay was performed as described (Kerkhoff and Rapp 1997) . GST-Rb(769-921) and anti-Cdk4 were purchased from Santa Cruz Biotechnology. Anti-p21
Cip1 and anti-p27 Kip1 were from Pharmingen.
Quantitative RNA analysis mRNA expression was evaluated by RT-PCR analysis using Real Time PCR (TaqMan, PE Applied Biosystems) (Gibson et al. 1996) . Reverse transcription of 2µg total RNA was performed in duplicate and further processed independently. PCR reaction (denaturation at 95°C for 2 min, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min; Sybr Green PCR Core Reagents, PE Applied Biosystems) was performed in triplicate and normalized to the endogenous cyclophilin mRNA level for each reaction. Target cDNA in transgenic mice was quantified using the delta-delta-CT method. Primer sequences are available on request.
Histopathological analysis
Hematoxylin/eosin and immunohistochemical analysis were performed as described previously (Wagner et al. 1998) . For in vivo BrdU labeling, animals were injected with BrdU (100 mg/kg body weight) intraperitoneally 3 h prior to sacrifice. Immunostaining for BrdU was performed using a monoclonal anti-BrdU antibody (1:400, Boehringer Mannheim). Labeling indices were calculated as fraction of BrdU-positive cells in relation to the total cell number and expressed as percentage ± SEM. For each time point, tubular complexes of four sections separated by 200 µm of at least three individual animals were evaluated.
Laser-captured microdissection and LOH analysis
Frozen or paraffin sections (5 µm) were applied to laser-capture microdissection (LCM; Arcturus Engineering, Mountain View, CA). Proteinase K-eluted genomic DNA was subjected to PCR amplification (1 mM dNTP, 15 pmole of each primer, 1.5 U AmpliTaqGold; PE Applied Biosystems) of the polymorphic markers located within 1-4-cM distance to the gene locus of interest. p53 (chromosome 11; 39 cM): D11Mit31 (40 cM), D11Mit320 (43cM), D11Mit177 (36cM); Ink4a/Arf (chromosome 4; 42.7 cM): D4Mit15 (42.6 cM), D4Mit145 (44.5 cM), D4Mit45 (42.5 cM); Smad4 (chromosome 18; 48 cM): D18Mit189 (48 cM), D18Mit210 (47 cM), D18Mit49 (49 cM); Rb1 (chromosome 14; 41 cM): D14Mit115 (40 cM), D14Mit69 (43 cM), D14Mit34 (40 cM). PCR products were visualized on 3% agarose or on polyacrylamide gel using fluorescence-labeled primers (ALFexpress II DNA Analysis system, Amersham Pharmacia Biotech). ratory for helpful discussion. This work was in part supported by grants from the Dr. Mildred Scheel-Stiftung, Bundesministerium fü r Bildung und Forschung and from the Deutsche Forschungsgemeinschaft (SFB518, B6) to R.M.S.
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